Phase 3 Study of BK1310 in Healthy Infants

Immunization; Infection Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02992925
• Other study ID #: BK1310-J01
• Status: Completed
• Phase: Phase 3
• Start date: November 2016
• Est. completion date: November 2018

Study information

• Verified date: February 2019
• Source: Mitsubishi Tanabe Pharma Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to:

• (cohort 1) evaluate safety and immunogenicity (Haemophilus influenzae type b, Hib) of BK1310.

• (cohort 2) evaluate efficacy and safety of BK1310 using ActHIB® and Tetrabik as a control in healthy infants.

Description:

• Arm: BK1310-High. Intervention: DPT-IPV-Hib-High(Combined Vaccine) 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.

• Arm: BK1310-Low. Intervention: DPT-IPV-Hib-Low(Combined Vaccine) 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.

• Arm: BK1310-High or Low. Intervention: DPT-IPV-Hib-High(Combined Vaccine) or DPT-IPV-Hib-Low(Combined Vaccine) 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals.

• Arm: ActHIB® and Tetrabik. Intervention: Hib vaccine and DPT-IPV 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 370
• Est. completion date: November 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Months to 43 Months

Eligibility

Inclusion Criteria:

• Healthy infants aged =2 and <43 months at the first vaccination of the study drug (recommended: =2 and <7 months). Those who are applicable of the following conditions must be carefully observed before the enrollment: infants with known underlying disease such as cardiovascular disease, renal disease, hepatic disease, blood dyscrasia, respiratory disease or developmental disorder. Infants who developed fever within 2 days after any previous vaccination. Infants with history of convulsions.

• Written informed consent is obtained from a legal guardian (parent)

Exclusion Criteria:

• With past diagnosis of immunodeficiency or currently under immunosuppressive treatment

• Have close relatives (the third degree of kinship) diagnosed with congenital immunodeficiency

• Possibility of anaphylaxis due to food or pharmaceuticals

• With experience of Hib infection, diphtheria, pertussis, tetanus or acute poliomyelitis

• With experience of Hib, diphteria, pertussis, tetanus or polio vaccination.

• Administered a live vaccine within 27 days before the first vaccination of the study drug, or inactivated vaccine or toxoid within 6 days before vaccination

• Administered transfusion, immunosuppressant (excluding drugs for external use), or immunoglobulin formulation

• Administered corticosteroid 2 mg/kg per day or more as prednisolone (excluding drugs for external use)

• Participated in other studies within 12 weeks before obtaining consent

• With the gestational age <37 weeks or weighed less than 2500 grams at birth.

• Considered to be not eligible by the principal investigators (sub-investigators) of the enrollment.

Related Conditions & MeSH terms

• Immunization; Infection

Intervention

Biological:
• DPT-IPV-Hib-High(Combined Vaccine)

• DPT-IPV-Hib-Low(Combined Vaccine)

• Hib vaccine

• DPT-IPV

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Mitsubishi Tanabe Pharma Corporation	The Research Foundation for Microbial Diseases of Osaka University

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antibody prevalence rate against anti-PRP with 1 µg/mL or higher, diphtheria toxin, pertussis, tetanus toxin, and polio virus		4 weeks after the primary immunization (Visit 4)
Secondary	Anti-PRP antibody prevalence rate with 0.15 µg/mL or higher		4 weeks after the primary immunization (Visit 4)
Secondary	Geometric mean antibody titer of anti-PRP antibody		4 weeks after the primary immunization (Visit 4)
Secondary	Anti-PRP antibody prevalence rate with 1 µg/mL or higher		4 weeks after the booster dose (Visit 6)
Secondary	Anti-PRP antibody prevalence rate with 0.15 µg/mL or higher		4 weeks after the booster dose (Visit 6)
Secondary	Geometric mean antibody titer of anti-PRP antibody		4 weeks after the booster dose (Visit 6)
Secondary	Geometric mean antibody titer against diphtheria toxin, pertussis, tetanus toxin, and polio virus		4 weeks after the primary immunization (Visit 4)
Secondary	Antibody prevalence rate against diphtheria toxin, pertussis, tetanus toxin, and polio virus		4 weeks after the booster dose (Visit 6)
Secondary	Geometric mean antibody titer against diphtheria toxin, pertussis, tetanus toxin, and polio virus		4 weeks after the booster dose (Visit 6)
Secondary	Number of participants with adverse events and adverse reactions	Cohort 1	Through the first dose (Visit 1) to 4 weeks after the booster dose (Visit 6)
Secondary	Number of participants with adverse events and adverse reactions	Cohort 2	Through the first dose (Visit 1) to 4 weeks after the primary immunization (Visit 4)